Tim Anderson
Stock Analyst at B of A Securities
(3.57)
# 852
Out of 4,754 analysts
25
Total ratings
57.14%
Success rate
7.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera, Inc. | Initiates: Buy | $38 | $27.46 | +38.38% | 1 | Feb 25, 2025 | |
| MRNA Moderna, Inc. | Maintains: Underperform | $41 → $34 | $29.46 | +15.41% | 2 | Feb 11, 2025 | |
| AMGN Amgen Inc. | Maintains: Underperform | $256 → $275 | $318.32 | -13.61% | 3 | Feb 6, 2025 | |
| MRK Merck & Co., Inc. | Maintains: Buy | $118 → $112 | $94.70 | +18.27% | 4 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $159 | $169.18 | -6.02% | 3 | Jan 23, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $25.99 | +11.58% | 1 | Dec 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Reinstates: Neutral | $63 | $60.31 | +4.46% | 1 | Dec 10, 2024 | |
| BIIB Biogen Inc. | Reinstates: Neutral | $178 | $145.59 | +22.26% | 1 | Dec 10, 2024 | |
| ABBV AbbVie | Reinstates: Neutral | $191 | $214.49 | -10.95% | 4 | Dec 10, 2024 | |
| REGN Regeneron Pharmaceuticals, Inc. | Reinstates: Underperform | $565 | $689.37 | -18.04% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $109 | $116.93 | -6.78% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $920.23 | +8.34% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $112.28 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $77.27 | - | 1 | Sep 22, 2017 |
Metsera, Inc.
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $27.46
Upside: +38.38%
Moderna, Inc.
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $29.46
Upside: +15.41%
Amgen Inc.
Feb 6, 2025
Maintains: Underperform
Price Target: $256 → $275
Current: $318.32
Upside: -13.61%
Merck & Co., Inc.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $94.70
Upside: +18.27%
Johnson & Johnson
Jan 23, 2025
Maintains: Neutral
Price Target: $160 → $159
Current: $169.18
Upside: -6.02%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $25.99
Upside: +11.58%
Bristol-Myers Squibb Company
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $60.31
Upside: +4.46%
Biogen Inc.
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $145.59
Upside: +22.26%
AbbVie
Dec 10, 2024
Reinstates: Neutral
Price Target: $191
Current: $214.49
Upside: -10.95%
Regeneron Pharmaceuticals, Inc.
Dec 10, 2024
Reinstates: Underperform
Price Target: $565
Current: $689.37
Upside: -18.04%
Dec 10, 2024
Reinstates: Buy
Price Target: $109
Current: $116.93
Upside: -6.78%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $920.23
Upside: +8.34%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $112.28
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $77.27
Upside: -